Dornheim G
Folia Haematol Int Mag Klin Morphol Blutforsch. 1982;109(6):856-62.
Thrombogenicity of prothrombin complex concentrates can be diminished by adding heparin to human citrate plasma, preferably before or during the adsorption of the prothrombin complex. Time, extent, and procedure of the heparin addition are dependent on the conditions of the initial material, the realization of the procedure and the provided application of the plasma supernatant after isolating the prothrombin complex. The procedure involves the use of buffer solutions containing heparin and antithrombin III. An activity of a procoagulatory effect cannot be identified in these preparations.
通过在人枸橼酸盐血浆中添加肝素，凝血酶原复合物浓缩物的血栓形成性可降低，最好在吸附凝血酶原复合物之前或期间添加。肝素添加的时间、程度和程序取决于初始材料的条件、程序的实施以及分离凝血酶原复合物后血浆上清液的预期应用。该程序涉及使用含有肝素和抗凝血酶III的缓冲溶液。在这些制剂中未发现促凝血作用的活性。
